Literature DB >> 34169405

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review.

Sedigheh Eskandari1, Soraya Sajadimajd2, Loghman Alaei3, Zhaleh Soheilikhah4, Hossein Derakhshankhah5, Gholamreza Bahrami6.   

Abstract

Neurodegenerative diseases such as stroke and Alzheimer's disease (AD) are two inter-related disorders that affect the neurons in the brain and central nervous system. Alzheimer's is a disease by undefined origin and causes. Stroke and its most common type, ischemic stroke (IS), occurs due to the blockade of cerebral blood vessels. As an important feature, both of disorders are associated with irreversible damages to the brain and nervous system. In this regard, finding common signaling pathways and the same molecular origin between these two diseases may be a promising way for their solution. On the basis of literature appraisal, the most common signaling cascades implicated in the pathogenesis of AD and stroke including notch, autophagy, inflammatory, and insulin signaling pathways were reviewed. Furthermore, current therapeutic strategies including natural and synthetic pharmaceuticals aiming modulation of respective signaling factors were scrutinized to ameliorate neural deficits in AD and stroke. Taken together, digging deeper in the common connections and signal targeting can be greatly helpful in understanding and unified treating of these disorders.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Neurodegenerative disorders; Signaling pathways; Stroke; Therapeutic strategy

Mesh:

Substances:

Year:  2021        PMID: 34169405     DOI: 10.1007/s12640-021-00381-7

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  73 in total

1.  An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Authors:  Theresa R Bomfim; Leticia Forny-Germano; Luciana B Sathler; Jordano Brito-Moreira; Jean-Christophe Houzel; Helena Decker; Michael A Silverman; Hala Kazi; Helen M Melo; Paula L McClean; Christian Holscher; Steven E Arnold; Konrad Talbot; William L Klein; Douglas P Munoz; Sergio T Ferreira; Fernanda G De Felice
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

Review 2.  Unregulated inflammation shortens human functional longevity.

Authors:  S A Brod
Journal:  Inflamm Res       Date:  2000-11       Impact factor: 4.575

Review 3.  Notch signaling: cell fate control and signal integration in development.

Authors:  S Artavanis-Tsakonas; M D Rand; R J Lake
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

Review 4.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.

Authors:  J W Baynes; S R Thorpe
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

Review 5.  Inflammation and Stroke: An Overview.

Authors:  Josef Anrather; Costantino Iadecola
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

6.  Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.

Authors:  Charles F Albright; Randy C Dockens; Jere E Meredith; Richard E Olson; Randy Slemmon; Kimberley A Lentz; Jun-Sheng Wang; R Rex Denton; Gary Pilcher; Paul W Rhyne; Joseph J Raybon; Donna M Barten; Catherine Burton; Jeremy H Toyn; Sethu Sankaranarayanan; Craig Polson; Valerie Guss; Randy White; Frank Simutis; Thomas Sanderson; Kevin W Gillman; John E Starrett; Joanne Bronson; Oleksandr Sverdlov; Shu-Pang Huang; Lorna Castaneda; Howard Feldman; Vlad Coric; Robert Zaczek; John E Macor; John Houston; Robert M Berman; Gary Tong
Journal:  J Pharmacol Exp Ther       Date:  2012-12-28       Impact factor: 4.030

7.  Modulation of mitochondrial function and autophagy mediates carnosine neuroprotection against ischemic brain damage.

Authors:  Seung-Hoon Baek; Ah Reum Noh; Kyeong-A Kim; Muhammad Akram; Young-Jun Shin; Eun-Sun Kim; Seong Woon Yu; Arshad Majid; Ok-Nam Bae
Journal:  Stroke       Date:  2014-06-17       Impact factor: 7.914

8.  Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade.

Authors:  Waleed Barakat; Nancy Safwet; Nabila N El-Maraghy; Mohamed N M Zakaria
Journal:  Eur J Pharmacol       Date:  2013-12-27       Impact factor: 4.432

9.  The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.

Authors:  Andre F Batista; Leticia Forny-Germano; Julia R Clarke; Natalia M Lyra E Silva; Jordano Brito-Moreira; Susan E Boehnke; Andrew Winterborn; Brian C Coe; Ann Lablans; Juliana F Vital; Suelen A Marques; Ana Mb Martinez; Matthias Gralle; Christian Holscher; William L Klein; Jean-Christophe Houzel; Sergio T Ferreira; Douglas P Munoz; Fernanda G De Felice
Journal:  J Pathol       Date:  2018-04-02       Impact factor: 7.996

View more
  2 in total

Review 1.  On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer's Disease.

Authors:  Jan Kriska; Zuzana Hermanova; Tomas Knotek; Jana Tureckova; Miroslava Anderova
Journal:  Int J Mol Sci       Date:  2021-09-07       Impact factor: 6.208

2.  Yi-Zhi-Fang-Dai Formula Exerts Neuroprotective Effects Against Pyroptosis and Blood-Brain Barrier-Glymphatic Dysfunctions to Prevent Amyloid-Beta Acute Accumulation After Cerebral Ischemia and Reperfusion in Rats.

Authors:  Zhongkuan Lyu; Qiyue Li; Zhonghai Yu; Yuanjin Chan; Lei Fu; Yaming Li; Chunyan Zhang
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.